콘텐츠로 건너뛰기
Merck

Discovery of a potent and selective aurora kinase inhibitor.

Bioorganic & medicinal chemistry letters (2008-08-06)
Johan D Oslob, Michael J Romanowski, Darin A Allen, Subramanian Baskaran, Minna Bui, Robert A Elling, William M Flanagan, Amy D Fung, Emily J Hanan, Shannon Harris, Stacey A Heumann, Ute Hoch, Jeffrey W Jacobs, Joni Lam, Chris E Lawrence, Robert S McDowell, Michelle A Nannini, Wang Shen, Jeffrey A Silverman, Michelle M Sopko, Bradley T Tangonan, Juli Teague, Josh C Yoburn, Chul H Yu, Min Zhong, Kristin M Zimmerman, Tom O'Brien, Willard Lew
초록

This communication describes the discovery of a novel series of Aurora kinase inhibitors. Key SAR and critical binding elements are discussed. Some of the more advanced analogues potently inhibit cellular proliferation and induce phenotypes consistent with Aurora kinase inhibition. In particular, compound 21 (SNS-314) is a potent and selective Aurora kinase inhibitor that exhibits significant activity in pre-clinical in vivo tumor models.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
SNS-314 mesylate, ≥98% (HPLC)